Capitalmind Flexi Cap Fund
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity & equity related instruments across market capitalization i.e. large-cap, mid-cap and small-cap stocks.
Growthvine rating: 1/5 — ranked #51 of 56 in category.
Fund basics
| Category | Equity: Flexi Cap |
|---|
| NAV | ₹10.48 (as of 2026-11-14) |
|---|
| AUM | ₹462 Cr |
|---|
| Expense ratio | 2.08% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Anoop Vijaykumar |
|---|
| Exit load | 1% for redemption within 1 month |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −10.25% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 80.6% of Nifty 500's upside and 72.8% of its downside.
Market cap allocation
| Large cap | 13.2% |
|---|
| Mid cap | 42.3% |
|---|
| Small cap | 44.5% |
|---|
Concentration
| Top 5 holdings | 21.6% |
|---|
| Top 10 holdings | 39.2% |
|---|
| Total holdings | 30 |
|---|
| Index overlap | 7.4% |
|---|
| Active share | 92.6% |
|---|
Top holdings
- Laurus Labs Limited — 5.3%
- Bank of maharashtra — 4.2%
- Divis Laboratories Ltd. — 4.1%
- Karur Vysya Bank Ltd. — 4.0%
- Federal Bank Ltd. — 4.0%
- Anand Rathi Wealth Limited — 3.7%
- Granules India Ltd. — 3.6%
- Multi Commodity Exchange of India Ltd — 3.5%
- Aurobindo Pharma Ltd. — 3.5%
- Shyam Metalics and Energy Limited — 3.4%
Top sectors
- Pharma & Biotech — 28.4%
- Banking & Financial — 28.3%
- Automobile — 9.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 2.6% | Q3 | #27 of 50 |